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Sensitivity of thyroglobulin (Tg) measurement in the follow-up of differentiated thyroid carcinoma (DTC) can be optimized by
using a sensitive Tg assay and rhTSH stimulation. We evaluated the diagnostic yield of a sensitive Tg assay and rhTSH
stimulated Tg in the detection of recurrences in the follow-up of DTC. Additionally the value of imaging techniques for the
localization of recurrences was evaluated. We included 121 disease free patients in long-term follow-up for DTC (median 10
years, range 1–34). Tg during thyroid hormone suppression therapy (Tg-on) and rhTSH stimulated Tg were measured with
a sensitive Tg assay. Patients with rhTSH stimulated Tg $1.0 ng/ml underwent imaging with neck ultrasound, FDG-PET and
post therapy
131I WBS. Sensitive Tg measurement resulted in 3 patients with Tg-on $1.0 ng/ml, recurrence could be localized
in 2 of them. RhTSH stimulation resulted in Tg $1.0 ng/ml in another 17 of 118 patients. Recurrence could be localized in only
1 additional patient (1 out of 118 patients). Recurrence was localized by neck ultrasound in 1 of 3, by FDG-PET in 2 of 3 and by
post therapy
131I WBS in 2 of 3 patients. In the detection of recurrences in DTC, rhTSH stimulation had very limited additional
value in comparison to Tg-on measurement with a sensitive Tg assay. We consider this too low to justify rhTSH stimulation in
all patients during long-term follow up. Neck ultrasound, FDG-PET and post therapy
131I WBS showed complementary value in
localization of disease, but were only positive in a small fracture of all procedures.
Citation: Persoon ACM, Jager PL, Sluiter WJ, Plukker JTM, Wolffenbuttel BHR, et al (2007) A Sensitive Tg Assay or rhTSH Stimulated Tg: What’s the Best
in the Long-Term Follow-Up of Patients with Differentiated Thyroid Carcinoma?. PLoS ONE 2(8): e816. doi:10.1371/journal.pone.0000816
INTRODUCTION
Although differentiated thyroid cancer (DTC) is characterized by
an excellent prognosis after thyroidectomy and radioiodine
ablation, recurrences occur often even many years after this initial
therapy [1]. Therefore, life long follow-up of DTC is recom-
mended. The clinical and economical relevance of optimal follow-
up with accurate diagnostic testing is crucial considering the large
population of patients in life long follow-up for DTC world-wide.
Traditionally, the cornerstone of follow-up is serum thyroglob-
ulin (Tg) measurement. Optimal sensitivity is reached when Tg is
measured during thyrotropin (TSH) stimulation because TSH
promotes Tg synthesis [2]. TSH stimulation can be simply achieved
by induction of hypothyroidism following thyroid hormone
withdrawal. However, externally administered recombinant human
TSH (rhTSH) has recently been proven to be an effective alternative
to thyroid hormone withdrawal. It stimulates the release of Tg by
thyroid remnants and metastatic lesions of DTC without inducing
the poorly tolerated side effects of hypothyroidism [3,4,5]. Besides
the availability of rhTSH, also the recent development of more
sensitive Tg assays may considerably increase the sensitivity of Tg
measurement to detect recurrent disease. New immunometric assays
(IMA) have a functional sensitivity as low as 0.1 ng/ml [6], possibly
allowing the detection of smaller amounts of thyroid tissue, even
when TSH is suppressed [7].
The current European guidelines for the follow-up of DTC [8]
recommend the use of a sensitive Tg assay that is standardized on
the European reference standard (CRM 457) [9,10] with
a functional sensitivity ,1.0 ng/ml. Additionally, the use of
rhTSH for Tg measurement is recommended for the first
evaluation 6–12 months after initial therapy to confirm the
adequacy of thyroidectomy and radioiodine ablation [8,11,12].
Although several studies [4,5] support the diagnostic accuracy of
rhTSH stimulated Tg measurement at the time of this first
evaluation, the optimal management of DTC patients concerning
Tg measurement in the long-term follow-up phase is less clear.
Some authors consider Tg measurement during thyroid hormone
suppression therapy (Tg-on) sufficient for the detection of
recurrences in low risk patients as long as Tg remains undetectable
[7,8,13]. Others favour periodic rhTSH stimulated Tg measure-
ment, arguing that tumour may exist in patients with an
undetectable Tg-on [11,12]. Prospective data about these issues
are lacking. Accordingly, the recently published American
Thyroid Association (ATA) management guidelines for patients
with differentiated thyroid cancer state that the timing or necessity
of subsequent rhTSH stimulated Tg testing is uncertain for those
found to be free of disease [14].
Recently, Smallridge et al. [6] questioned if a Tg assay with
improved sensitivity could eliminate the need for rhTSH
stimulation when Tg during thyroid hormone suppression therapy
is ,1.0 ng/ml. This retrospective study showed that when using
a sufficiently sensitive Tg assay, these patients rarely have a rhTSH
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PLoS ONE | www.plosone.org 1 August 2007 | Issue 8 | e816stimulated Tg.2 ng/ml and only one of 80 patients had detectable
disease. This recurrence was demonstrated by ultrasound despite
numerous imaging studies. Additionally, the lack of localizable
disease in a significant part of patients with detectable stimulated Tg,
brings up for discussion, whether this stimulation is useful. The lack
of evidence that the early detection of especially local disease will
improve prognosis actualizes this question even more [15,16].
For the detection of recurrent disease several imaging methods
are used. Neck ultrasound has established a fixed place in the
follow-up of DTC, particularly for the detection of cervical lymph
node metastasis [17]. The timing and the method of choice for
additional imaging is less clear. Applied methods are post therapy
131I whole body scan (WBS), CT scan of the neck and chest, FDG-
PET scan, and MRI.
In this study we evaluated the introduction of a highly sensitive
Tg assay [18] and the additional value of rhTSH stimulation, for
the detection of recurrences in disease free patients in long-term
follow-up for DTC. Additionally, we evaluated the value of
different imaging techniques including neck ultrasound, FDG-
PET scan and post therapy
131I WBS in the localization of
recurrent disease in Tg positive patients.
METHODS
Study Population
All patients who were treated and followed for DTC in the
University Medical Centre Groningen (UMCG) between 1978
and 2003 and were disease free were eligible for participation.
Disease free was defined as no clinical evidence of recurrent or
persistent DTC and undetectable Tg-on for at least 1 year. This
Tg level had been routinely measured by an immunoradiometric
assay (CIS Bio International, Gif-sur-Yvette, France) with a de-
tection limit of 1.5 ng/ml for many years. Exclusion-criteria were
age under 18 years or above 75 years, pregnancy and severe
psychiatric illness. Additionally, patients testing positive for Tg
antibodies were excluded.
All patients had undergone initial treatment consisting of total
thyroidectomy, followed by radioiodine ablation therapy. Addi-
tional treatment, such as lymph node dissection and additional
131I
therapy was performed when indicated. Routine follow-up
included visits at the outpatient clinic every four months in the
first two years, and thereafter annually. At each visit physical
examination of the neck, Tg-on and TSH measurement were
performed. Patients used a suppressive dose of levothyroxin. All
patients gave written informed consent to participate in the study,
which was approved by the medical ethical review committee of
the University Medical Centre Groningen.
Study design
At baseline, Tg-on was measured with a new sensitive Tg assay (see
‘‘Serum measurements’’ section) in all patients. Subsequently, all
patients underwent rhTSH stimulated Tg measurement. Patients
with rhTSH stimulated Tg $1.0 ng/ml underwent additional
imaging including FDG-PET scanning, neck ultrasound and post
therapy
131I BS to detect recurrent disease. After 3 months Tg-on
and rhTSH stimulated Tg measurement were repeated.
RhTSH stimulated Tg measurement RhTSH (Thyrogen,
Genzyme Corporation, Cambridge, MA) was administered
intramuscularly (i.m) at a dose of 0.9 mg once a day for two
consecutive days, while maintaining thyroid hormone suppression
therapy. Seventy-two hours after the second rhTSH injection, Tg
and TSH were measured.
Imaging studies and radioiodine treatment For detection
of recurrent disease, patients underwent 18-F Fluorodeoxyglucose
(FDG) Positron Emission Tomography (PET), ultrasound
examination of the neck (with fine needle aspiration when
indicated) and treatment with 150 mCurie
131I followed by
a post therapy
131I whole body scan (WBS).
FDG-PET scan was performed during thyroid hormone with-
drawal, using an ECAT HR+ camera (Siemens/CTI, Knoxville,
TN). Patients fasted overnight before the investigation. Ninety
minutes after intravenous injection of 5 MBq/kg of FDG, a 2-D
whole-body image was acquired from top of the skull to the knees.
Images were reconstructed using iterative methods with attenuation
correction. Emission time was 5 minutes and transmission time was
3 minutes.
Ultrasound of the neck was performed by an experienced and
dedicated radiologist using a Siemens machine with a linear
13 MHz transducer, with fine needle aspiration of suspicious
lymph nodes or masses. Lymph nodes with short axis $10 mm
and/or round oval shape, unsharp borders, inhomogeneous
pattern (in particular calcifications or cystic changes), absence of
echogenic hilus or hypoechoic pattern [17,19,20] were biopsied
with percutaneous fine needle aspiration. In case of a hot spot in
the neck on the FDG-PET scan, this information was passed to the
radiologist who tried to puncture this specific node.
Post therapy
131I WBS was performed with a two-headed
gammacamera (Multispect 2, Siemens) with a high-energy collima-
tor. We acquired three to four 10-minute adjacent spot views
covering the whole body in anterior and posterior views. When
necessary, additional views were obtained. The post therapy
131I
WBS was performed 10 days afterthe administration of 150 mCurie
131I. Alltheseimaging procedures wereperformed within two weeks.
Additional imaging, including magnetic resonance imaging (MRI)
and computed tomography (CT) imaging was performed to confirm
positive findings on either post therapy 131I WBS or FDG-PET
scan. Levothyroxin was stopped six weeks before radioiodine
treatment and replaced by triiodothyronine until two weeks before
radioiodine treatment. Levothyroxin was restarted after the
treatment. A low iodine diet was followed during one week before
treatment. Tg and TSH were measured six weeks after thyroid
hormone withdrawal (Tg-off), on the day of the 131I treatment.
To evaluate the effect of radioiodine treatment, we repeated Tg-
on and rhTSH stimulated Tg measurement four months after
treatment with 150 mCurie
131I.
Evaluation of imaging and final disease status All
imaging, radiological and nuclear images were evaluated and
compared with previous scans by an independent expert panel
consisting of endocrinologists, nuclear medicine physicians and
a head-neck surgeon, aided by a radiologist when required.
Disease status of each patient was assessed and categorized as ‘‘no
recurrence localized’’ or ‘‘recurrence localized’’. ‘‘Recurrence
localized’’ implied one or more abnormal imaging studies strongly
suggestive of recurrent or metastatic thyroid carcinoma. ‘‘No
recurrence localized’’ implied negative radiological and nuclear
imaging. Subsequently, the expert panel determined the
therapeutic consequences of the findings.
Serum measurements
Before inclusion in this study, during routine follow-up, Tg was
measured by an immunoradiometric assay with functional sensitivity
of 1.5 ng/ml (Cis Bio International, Gif-sur-Yvette, France). During
the study, Tg was measured by a more sensitive assay (Nichols
AdvantageH Tg assay, Nichols Institute Diagnostics, San Clement,
CA, USA). This is a fully automated chemiluminescence sandwich
immunoassay with functional sensitivity of 0.6 ng/ml and calibrated
against the CRM-457 reference preparation [18].
RhTSH Stimulated Tg in DTC
PLoS ONE | www.plosone.org 2 August 2007 | Issue 8 | e816TSH was measured by a time-resolved fluoroimmunoassay
using the DELFIA system (PerkinElmer Life Sciences, Turku,
Finland) with a detection limit of 0.003 mU/l. Tgab were
measured by a chemiluminescence immunoassay (Nichols Advan-
tage, Nichols Institute Diagnostics, San Clement, CA, USA) with
a cut-off value for TgAb positivity of 2 IU/ml [21]. All serum
measurements were performed in the same institution (UMCG).
Statistical analysis
Data are expressed as median and range. The differences in Tg
and TSH before and after radioiodine treatment were analysed
using the Wilcoxon test for paired data. For statistical reasons, Tg
values ,0.6 were considered to be equal to 0.6 ng/ml and TSH
values ,0.003 were considered to be equal to 0.003 mU/L in this
test. P-values of less than 0.05 were considered to indicate
statistical significance. Statistical analysis was performed using
SPSS version 10.0 software (SPSS, Inc., Chicago, IL.).
RESULTS
Study patients
Hundred twenty-one patients with DTC (female 76%, median age
54 years, median follow-up 10 years (range 1–34) after initial
surgery) were studied (Table 1). Patients were divided in three
groups on the basis of Tg-on result.
Group 1: Patients with Tg-on $1.0 ng/ml In three
patients Tg-on was $1.0 ng/ml (table 2). As expected, in these
three patients Tg after rhTSH was also $1.0 ng/ml. Imaging
resulted in the localization of a recurrence in two of them. In
patient A (Tg-on 1.1 ng/ml) no recurrence could be identified on
FDG-PET scan, neck ultrasound, post therapy
131I WBS or MRI
Table 1. Disease characteristics.
..................................................................................................................................................
Characteristic All patients N=121
Patients with undetectable
Tg-on N=115
Patients with Tg-on
0.6-1.0 ng/ml N=3
Patients with
Tg-on$1.0 ng/ml N=3
Sex–no. (%)
Female 92 (76) 89 (77) 2 (67) 1 (67)
Male 29 (24) 26 (13) 1 (33) 2 (33)
Age
a (yrs) 54 (43–61) 54 (43–61) 49 (33–51) 56 (31–64)
Histology–no. (%)
Papillary 86 (71) 81 (70) 3 (100) 2 (67)
Follicular 29 (24) 29 (25) 00
Hu ¨rthle cell 6 (5) 5 (4) 01 (33)
Follow-up
a (yrs) 10 (6–16) 10 (6–16) 8 (5–27) 16 (5–23)
TNM-classification
b–no. (%)
T1-T3 100 (82) 96 (84) 3 (100) 1 (33)
T4 3 (3) 2 (2) 01 (33)
Tx 18 (15) 17 (15) 01 (33)
N0 85 (70) 84 (73) 1 (33) 0
N1 32 (27) 27 (24) 2 (67) 3 (100)
Nx 4 (3) 4 (4) 00
M0 120 (99) 114 (99) 3 (100) 3 (100)
M1 1 (1) 1 (1) 00
TNM-stage
b–no. (%)
,45 years
stage I 72 (60) 68 (59) 3 (100) 1 (33)
stage II 0 0 0 0
.45 years
stage I 5 (4) 5 (4) 00
stage II 26 (21) 26 (23) 00
stage III 11 (9) 9 (8) 02 (67)
stage IV 1 (1) 1 (1) 00
unknown 6 (5) 6 (5) 00
Risk-group
c–no. (%)
Low-risk 103 (85) 99 (86) 3 (100) 1 (33)
High-risk 12 (10) 10 (9) 02 (67)
Unknown 6 (5) 6 (5) 00
aData are medians with interquartile range (25
th and 75
th centile) in the groups ‘‘All patients, n=121’’ and ‘‘Patients with undetectable Tg-Tg-on’’, N=115’’.
Data are medians and range in the groups ‘‘Patients with Tg-on 0.6–1.0 ng/ml, N=3’’and ‘‘Patients with Tg-on .1.0, N=3’’.
bTNM-classification and staging according to Hermanek & Sobin, 1992 [34].
cLow-risk patients are stage I disease if younger than 45 years or Stage I or II if older than 45 years.
doi:10.1371/journal.pone.0000816.t001
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PLoS ONE | www.plosone.org 3 August 2007 | Issue 8 | e816scan of the neck region (Table 3). In patient B (Tg-on 1.3 ng/ml),
recurrence was located in the lower jugular region and identified
on neck ultrasound, MRI and CT scan. There was no
131I uptake.
Selective neck dissection was performed and three malignant
lymph nodes were removed. Patient C (Tg-on 2.8 ng/ml) had an
extensive paravertebral/mediastinal recurrence, identified on
FDG-PET scan, post therapy
131I WBS, and a subsequent MRI,
CT scan and octreotide scintigram. This tumour was inoperable
and not amenable to radioiodine or octreotide therapy. External
radiotherapy with palliative intention was started. Patient died
from respiratory insufficiency due to the consequences of
metastatic thyroid carcinoma, eleven months after the
identification of recurrent disease.
Tg-on measurement (table 2) was repeated 4 months after
radioiodine treatment (before neck dissection in patient B and the
start of radiotherapy in patient C, patient A refused Tg
measurement). Tg-on was lower but remained detectable in both
patients (table 3). Only in patient B rhTSH stimulated Tg
measurement was repeated after radioiodine therapy (patient A
refused and patient C was not stimulated because of extensive
disease). RhTSH stimulated Tg was 6.7 ng/ml before radioiodine
therapy and 5.3 ng/ml after radioiodine therapy.
Group 2: Patients with Tg-on 0.6–1.0 ng/ml Three patients
(table 2) had detectable Tg-on levels between 0.6 and 1.0 ng/ml
(0.76, 0.81 and 0.99 ng/ml). After rhTSH stimulation Tg was
undetectable in the first patient and rose to 1.3 and 8.6 ng/ml in the
two other patients. These two patients were referred for imaging. In
none of them recurrence was localized (table 4).
Four months after radioiodine treatment Tg-on and rhTSH
stimulated Tg were measured again (table 4). Tg-on after
radiodine treatment remained detectable in one of both patients
(2.6 ng/ml). At the second rhTSH stimulated Tg measurement,
Tg remained detectable in both patients (0.96 and 10.0 ng/ml).
Group 3: Patients with undetectable Tg-on (,0.6 ng/
ml) Tg-on was undetectable in 115 patients. After rhTSH
stimulation, Tg became detectable in 19 patients (table 2). In 15
patients (13%) rhTSH stimulated Tg was $1.0 ng/ml (median
1.6 ng/ml, range 1.0–5.4). Imaging was performed in 14 out of
these 15 patients with undetectable Tg-on and rhTSH stimulated
Tg $1.0 ng/ml. One patient refused imaging because of
pregnancy wish. After evaluation of all images, recurrence was
localized in one of 14 patients (table 5). Recurrence was localized
in patient F and was located in the right supraclavicular fossa and
identified on FDG-PET scan, post therapy
131I WBS and MRI
scan. The suspicious lesion was resected and histopathological
analysis showed a lymph node metastasis of papillary thyroid
carcinoma. In the remaining 13 patient no recurrence could be
localized.
Four months after radioiodine treatment (and before surgery in
patient F), Tg-on and rhTSH stimulated Tg were measured again
(table 2). Tg-on had become detectable in 1 of 14 patients, Tg and
TSH levels did not significantly differ (p=0.4 and 0.7) compared
to the situation before radioiodine treatment. At the second
rhTSH stimulated Tg measurement, Tg remained detectable in 13
of 14 patients but was significantly lower (p=0.005) than before
radioiodine treatment while no difference in TSH was found
(p=0.084).
Diagnostic yield of imaging tests Imaging studies were
performed in 19 of 20 patients with rhTSH stimulated Tg
$1.0 ng/ml (one patient refused because of pregnancy wish). All
these patients underwent neck ultrasound, FDG-PET scan and
post therapy
131I WBS. Additional imaging including MRI, CT
and Octreotide scanning was performed when better anatomical
localization was needed or when results were contradicting. Only
in three patients recurrence could be localized.
In patient B (table 3) recurrence was localized in the neck and
was initially detected by neck ultrasound. FDG-PET scan and post
therapy
131I WBS were negative. Exact anatomical localization was
achieved by CT and MRI. Patient C (table 3) had extensive
metastatic disease, which was visualized by nuclear medicine
methods (FDG-PET, radioiodine imaging, octeotride scintigraphy)
as well as CT and MRI. Patient F (table 5) with a supraclavicular
lesion had a negative ultrasound and positive FDG-PET, post
therapy
131I WBS and MRI.
Table 2. Serum Tg and TSH levels.
..................................................................................................................................................
Patients with Tg-on
$1.0 ng/ml
a (N=3)
Patients with Tg-on
0.6-1.0 ng/ml
a (N=3)
Patients with Tg-on
,0.6 ng/ml
g (N=115)
Tg-on (ng/ml)
b 1.3 (1.1–2.8) 0.81 (0.76–0.99) ,0.6
TSH (mU/l) 0.04 (0.004–0.075) 0.014 (0.003–2.4) 0.048 (0.017–0.31)
Tg after rhTSH (ng/ml) 5.3 (4.5–6.7) 1.3 (,0.6–8.6) ,0.6 (,0.6–,0.6)
TSH (mU/l) 13 (9.2–19) 7.4 (14.0–15.0) 14.0 (9.8–20.0)
Tg-off (ng/ml)
c 8.1 (3.5–10.0) 2.6/20.0
e 3.75 (1.65–6.78)
f
TSH (mU/l) 16.0 (21.0–46.0) 48.0/50.0 46.5 (35.5–53.5)
Tg-on (ng/ml), 4 months after radioiodine treatment 1.0 (0.84–1.9) ,0.6/2.6
e ,0.6 (,0.6–,0.6)
f
TSH (mU/l) 0.018 (0.014–0.022) 0.019/0.11 0.03 (0.008–0.46)
Tg after rhTSH (ng/ml), 4 months after radioiodine treatment 5.3
d 0.96/10.0
e 1.35 (0.99–1.95)
f
TSH (mU/l) 26 17/26 14.5 (9.9–21.5)
aData are medians with range.
bTg-on: Tg during thyroid hormone suppression therapy.
cTg-off: Tg after 6 weeks thyroid hormone withdrawal.
dN=1: RhTSH stimulated Tg measurement, 4 months after radioiodine treatment was performed in one of three patients. One patient refused, the second patient was
not stimulated because of extensive disease.
eN=2: RhTSH stimulated Tg was $1.0 ng/ml in 2 patients, these patients were referred for imaging.
fN=14: RhTSH stimulated Tg was $1.0 ng/ml in 15 patients, imaging was performed in 14 patients. In one patient imaging was not performed because of pregnancy
wish.
gData are medians with interquartile range (25
th and 75
th centile)
doi:10.1371/journal.pone.0000816.t002
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This prospective study showed that the introduction of a new
sensitive Tg assay for clinical disease free patients resulted in the
localisation of 2 recurrences (1.8%) in a cohort of 121 patients
considered to be in remission. The additional yield of rhTSH
stimulation in these patients was 1 additional localized recurrence
(1/118 patients, 0.8%). We consider this too low to justify rhTSH
stimulation in all patients. These results confirm the retrospective
data recently presented by Smallridge et al. [6].
Although the presence of the established risk factors result in
a reduced life expectancy [22], also initial low risk patients can die
from thyroid cancer [23], illustrating that distinction between high
and low risk is limited [24]. Therefore in this study, we included
patients irrespective of prognostic factors influencing risk of
recurrence. Additionally, most recurrences occur within the first
decade after initial therapy, but up to one third of recurrences
occur in the subsequent years. Recurrences are described even
more than 40 years after initial diagnosis [1]. Therefore, lifelong
follow-up is advised [8]. We included patients regardless of follow-
up duration. By doing so, this study population consisted of
a mixture of low-risk and high-risk patients and variable follow-up
duration, reflecting the variety of patients in follow-up for DTC in
daily clinical practice [25] and results of this study are applicable
to all patients with DTC in follow-up for DTC.
Tg measurement is the cornerstone in the follow-up of DTC but
accurate measurement of Tg is technically challenging. An
important requirement of Tg assays is a functional sensitivity low
enough to detect small amounts of thyroid tissue when TSH is
suppressed [7]. The importance and surplus value of a sensitive Tg
assay has been shown in this study. Two patients with recurrent
disease could be identified solely on the basis of Tg-on levels
$1.0 ng/mlbyusingasensitiveTgassay.In2of3patients,withTg-
on $1.0 ng/ml recurrent disease could be localized so diagnostic
yield of imaging was high when using 1.0 ng/ml as cut-off. Tg-on in
these patients had been undetectable by the conventional assay, so
formerly rhTSH stimulated Tg measurement would have been
needed to identify these patients. These patients are illustrative that
optimizing sensitivity of Tg assays, may obviate the need for rhTSH
stimulated Tg measurement in the future follow-up of DTC [26].
In one patient with undetectable Tg-on, recurrent disease was
found. Only in this patient (1 of 121 patients) rhTSH stimulated
Tg measurement had additional diagnostic yield in the detection
of recurrent disease. Clearly, this very limited result of rhTSH
testing does not validate the introduction of routine rhTSH
stimulated Tg measurement in the follow-up of DTC. Moreover,
regular serial Tg-on measurement with a sensitive Tg assay
anyhow would have identified this solely patient, since the change
in Tg over time is more informative than a single Tg
determination [27]. Tg-on will increase during serial Tg-on
measurement [28,29] when recurrent disease is actually present.
Zanotti-Fregonara et al. [30], also evaluated the utility of rhTSH
stimulation. Their results endorse the limited value of periodic
rhTSH stimulation in patients with stage I thyroid cancer. In
contrast, they recommend rhTSH stimulation in higher-risk patients
because ofpositive TglevelsafterrhTSHin4 of 35 high-riskpatients
(11%). However, two of these patients already had detectable Tg-on
levels. In only one patient, recurrence was localized 10 months after
the last I-131 therapy, and according to our definition this patient
could not be considered as in remission. Results of our study do not
support the use of rTSH stimulation in the long term follow up of
high risk patients. Recurrent disease was localized in one low risk
patient with undetectable Tg-on after rhTSH stimulation l (patient
F) and in one low-risk and one high risk patient using the ultra
sensitive Tg assay (patient B and C respectively)
Uncertainty exists about the clinical value of low but detectable
Tg-on values in sensitive Tg assays. In the present study a small
number of patients had Tg-on levels between 0.6 and 1.0 ng/ml.
The rise in Tg after rhTSH to $1.0 ng/ml in 2 of these 3 patients
indicated residual thyroid tissue and not an assay artefact [31].
Nevertheless, recurrent disease could not be localized. This
illustrates that the sensitivity of Tg measurement currently exceeds
the sensitivity of the available imaging techniques and therefore
careful watching of the slope of Tg-on is recommended. The
optimal timing of imaging needs to be ascertained in future
studies. Extensive imaging when Tg-on in a sensitive assay rises
above a certain cut-off level will be far more efficient, preventing
needless patient burden and medical costs.
In the present study, imaging including post therapy
131IW B S ,
neck US and FDG PET was performed in all patients suspected of
recurrent disease. Neck ultrasound is considered the most sensitive
method todetectlocal recurrence,althoughitisnot specificandisan
operator-dependent procedure [8,32]. In contrast, radioiodine
scanning has high specificity for recurrences of differentiated thyroid
cancer but considerably low sensitivity [32]. Particularly in radio-
iodine negative differentiated thyroid cancer, FDG-PET is useful
and hasboth high sensitivity andspecificity [33].Results of thisstudy
showed that these three imaging methods are complementary in the
detection of recurrent disease. Nevertheless, additional imaging
including CT and MRI scanning was needed to provide better
anatomical localization of lesions. This result illustrates that the
fusion of anatomy and metabolism by the recently introduced
integrated PET/CT systems, is a promising technique [32,33].
Finding a low or undetectable Tg after rhTSH stimulation could
be considered as a reassurance to patients that truly no disease
activity is present. In the present study, Tg was ,1.0 ng/ml after
rhTSH in the vast majority (87%) of patients. Actually, this result
only confirmed the already known absence of disease in these
patients with undetectable Tg-on. In this group of patients, rhTSH
stimulation is an expensive, unnecessary diagnostic test. Moreover,
these data underscore the adequacy of undetectable Tg-on
confirming the absence of disease and contradict the opinion that
‘‘an undetectable serum Tg measured during thyroid hormone
suppression is often misleading in a large proportion of patients with
residual DTC’’ [7]. We did not routinely use neck ultrasound during
follow-up so we could have missed small lymph node metastases in
these patients. For it is known that lymph node metastases can be
detected by neck ultrasound in patients with both undetectable Tg-
on and undetectable rhTSH stimulated Tg or Tg-off [16,17]. This is
the reason why the combination of Tg measurement and neck
ultrasound is now becoming the standard of care, although it is still
controversial whether the early detection of generally very small
lymph node metastases will improve prognosis [15,16].
In conclusion, Tg measurement with a sensitive Tg assay has an
additional diagnostic yield in the detection of recurrent disease in
patients in follow-up for DTC and practically obviates the need for
rhTSH stimulated Tg measurement. Long-term follow up of DTC
can safely be based on serial Tg-on measurement with a sensitive Tg
assay and additional diagnostic tests should be performed only when
Tg-on rises above an established cut-off level. This will result in
a limited follow up protocol, warranting the detection of recurrences
of DTC and reducing patient burden and medical costs.
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